Research location

Rennes

France

Published trials939

Site observations963

Linked trials published939

Page1 / 19

Research activity in Rennes

France

CureCurrent currently publishes aggregate city-level research activity for this location: 939 trials and 963 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Rennes

939 linked trials · page 1 of 19

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerNCT07701941 · 2026-09-17 · 1 site observation

Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial FibrillationNCT07436299 · 2026-09-01 · 1 site observation

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation

Skipping Hormone Therapy in Low-Risk Early Breast CancerNCT07661927 · 2026-07-06 · 1 site observation

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsNCT07106632 · 2026-06-26 · 1 site observation

Predicting Response to Immunochemotherapy in Early Triple Negative Breast CancerNCT07570524 · 2026-06-25 · 1 site observation

Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of ObesityNCT07378072 · 2026-06-17 · 1 site observation

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.NCT07333066 · 2026-06-05 · 1 site observation

Longitudinal Study on the Sustainability of Transcranial Magnetic Stimulation Protocols - BiomarkersNCT07684911 · 2026-06-04 · 1 site observation

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · 2026-05-22 · 1 site observation

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveNCT07413939 · 2026-05-21 · 1 site observation

Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of CancerNCT07436312 · 2026-05-04 · 1 site observation

Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaNCT07234058 · 2026-04-02 · 1 site observation

EXOPULSE Suit and Walking Ability of Patients With Multiple SclerosisNCT07252895 · 2026-03-30 · 1 site observation

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)NCT07282574 · 2026-03-10 · 1 site observation

Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate CancerNCT07189598 · 2026-03-02 · 1 site observation

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)NCT06937905 · 2026-02-06 · 1 site observation

Stratification of Arrhythmic Risk and/or Heart Failure Risk in Patients With Hereditary Heart DiseaseNCT07257289 · 2026-02-03 · 1 site observation

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerNCT07193394 · 2026-01-31 · 1 site observation

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsNCT07195695 · 2026-01-16 · 1 site observation

Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)NCT06225505 · 2026-01-05 · 1 site observation

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerNCT07225946 · 2025-12-19 · 1 site observation

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibNCT07237256 · 2025-12-18 · 1 site observation

Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET)NCT06280742 · 2025-12-16 · 2 site observations

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559 · 2025-12-10 · 1 site observation

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisNCT07225504 · 2025-11-11 · 1 site observation

Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung CancerNCT06656598 · 2025-11-07 · 1 site observation

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe AsthmaNCT07219173 · 2025-10-22 · 1 site observation

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.NCT07195344 · 2025-10-15 · 1 site observation

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerNCT07100106 · 2025-10-07 · 1 site observation

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811 · 2025-10-02 · 1 site observation

Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillation (AF), Heart Failure and Preserved Ejection Fraction: Heart Rate Regularization Versus Medical Rate ControlNCT06833138 · 2025-09-10 · 1 site observation

Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting ListNCT06868797 · 2025-08-29 · 1 site observation

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)NCT07098338 · 2025-08-07 · 1 site observation

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803 · 2025-08-06 · 1 site observation

Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)NCT07243132 · 2025-07-02 · 1 site observation

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibNCT06620835 · 2025-06-19 · 2 site observations

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantNCT06563895 · 2025-05-12 · 1 site observation

Preoperative Magnetic Tracking in Breast Surgery in France: French Medical-economic Study.NCT06906601 · 2025-04-15 · 1 site observation

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06790693 · 2025-04-09 · 1 site observation

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerNCT06801834 · 2025-04-04 · 1 site observation

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerNCT06890598 · 2025-03-27 · 1 site observation

Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic EpisodeNCT05384392 · 2025-03-27 · 1 site observation

Enabling Women With Parkinson's Disease to Identify and Better Manage Hormonal Triggers of Parkinsonian SymptomsNCT06582212 · 2025-03-12 · 1 site observation

Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple SclerosisNCT06592703 · 2025-03-06 · 1 site observation

Evaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive EpisodeNCT06601140 · 2025-03-05 · 1 site observation

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 · 2025-02-27 · 1 site observation

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerNCT06712355 · 2025-02-03 · 1 site observation

Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.NCT06450314 · 2025-01-25 · 1 site observation

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World ContextNCT06487078 · 2025-01-20 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.